Serotonin Receptor Agonists
"Serotonin Receptor Agonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Endogenous compounds and drugs that bind to and activate SEROTONIN RECEPTORS. Many serotonin receptor agonists are used as ANTIDEPRESSANTS; ANXIOLYTICS; and in the treatment of MIGRAINE DISORDERS.
| Descriptor ID |
D017366
|
| MeSH Number(s) |
D27.505.519.625.850.800 D27.505.696.577.850.800
|
| Concept/Terms |
Serotonin Receptor Agonists- Serotonin Receptor Agonists
- Agonists, Serotonin Receptor
- 5-HT Agonists
- 5 HT Agonists
- Agonists, 5-HT
- 5-Hydroxytryptamine Agonists
- 5 Hydroxytryptamine Agonists
- Agonists, 5-Hydroxytryptamine
- 5-Hydroxytrytamine Agonist
- 5 Hydroxytrytamine Agonist
- Agonist, 5-Hydroxytrytamine
- Receptor Agonists, Serotonin
- Serotonergic Agonists
- Agonists, Serotonergic
- Serotonin Agonist
- Agonist, Serotonin
- Serotonin Agonists
- Agonists, Serotonin
- Serotonin Receptor Agonist
- Agonist, Serotonin Receptor
- Receptor Agonist, Serotonin
- 5-HT Agonist
- 5 HT Agonist
- Agonist, 5-HT
- Serotonergic Agonist
- Agonist, Serotonergic
|
Below are MeSH descriptors whose meaning is more general than "Serotonin Receptor Agonists".
Below are MeSH descriptors whose meaning is more specific than "Serotonin Receptor Agonists".
This graph shows the total number of publications written about "Serotonin Receptor Agonists" by people in this website by year, and whether "Serotonin Receptor Agonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 0 | 1 | 1 |
| 2010 | 1 | 1 | 2 |
| 2013 | 0 | 1 | 1 |
| 2017 | 1 | 1 | 2 |
| 2018 | 3 | 0 | 3 |
| 2019 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Serotonin Receptor Agonists" by people in Profiles.
-
Almotriptan: a review of 20 years' clinical experience. Expert Rev Neurother. 2019 08; 19(8):759-768.
-
Opioid-Induced Constipation (OIC) Guideline. Gastroenterology. 2019 01; 156(1):228.
-
American Gastroenterological Association Institute Guideline on the Medical Management of Opioid-Induced Constipation. Gastroenterology. 2019 01; 156(1):218-226.
-
Formulation and Evaluation of Niosomal in situ Nasal Gel of a Serotonin Receptor Agonist, Buspirone Hydrochloride for the Brain Delivery via Intranasal Route. Pharm Nanotechnol. 2018; 6(1):69-78.
-
Menstrual migraine: a review of current and developing pharmacotherapies for women. Expert Opin Pharmacother. 2018 02; 19(2):123-136.
-
Lasmiditan for the treatment of migraine. Expert Opin Investig Drugs. 2017 Feb; 26(2):227-234.
-
Comparison of frovatriptan plus dexketoprofen (25 mg or 37.5 mg) with frovatriptan alone in the treatment of migraine attacks with or without aura: a randomized study. Cephalalgia. 2014 May; 34(6):434-45.
-
A microdialysis study of ST1936, a novel 5-HT6 receptor agonist. Neuropharmacology. 2011 Mar; 60(4):602-8.
-
Evolution of migraine-associated symptoms in menstrually related migraine following symptomatic treatment with almotriptan. Neurol Sci. 2010 Jun; 31 Suppl 1:S115-9.
-
Effects of systemic 5-HT(1B) receptor compounds on ventral tegmental area intracranial self-stimulation thresholds in rats. Eur J Pharmacol. 2009 Feb 14; 604(1-3):74-8.